Skip to main content
TipRanks
Go Ultimate75% OFF

Jeffrey Brennan Insider Profile

4 Followers

Jeffrey Brennan, SVP, Bus. and Comm. Dev. & CBO at Gyre Therapeutics, holds 0.00 shares in Gyre Therapeutics (Ticker: GYRE).

Jeffrey Brennan's Trading History

GYRE
Gyre Therapeutics
Mar 03, 2011SVP, Bus. and Comm. Dev. & CBOUninformative Sell37.92K$0.00
GYRE
Insider Shares: 0.00 (0.00%)
DateTransactionAmountNo. of SharesPrice per ShareProfitLink to Report
Mar 03, 2011Uninformative Sell$37.92K1,264$30.00―
Dec 14, 2010Informative Sell$238.50K10,000$23.85+67.40%
Dec 15, 2009Informative Sell$1.98M94,759$20.90-11.40%
Oct 21, 2009Uninformative Sell$438.16K19,778$22.15―
Aug 12, 2009Informative Sell$189.30K15,000$12.62-53.70%

You May Also Like

Jeffrey Brennan insider profile FAQ

What is the percentage of profitable transactions made by Jeffrey Brennan?
The percentage of profitable transactions made by Jeffrey Brennan is 33%.
What is the average return per transaction made by Jeffrey Brennan?
The average return per transaction made by Jeffrey Brennan is 0.70%.
What stocks does Jeffrey Brennan hold?
Jeffrey Brennan holds: GYRE stocks.
What was Jeffrey Brennan’s latest transaction?
Jeffrey Brennan’s latest transaction was an Uninformative Sell of $37.92K.
What was Jeffrey Brennan's most profitable transaction?
Jeffrey Brennan’s most profitable transaction was an Informative Sell of GYRE stock on December 14, 2010. The return on the trade was 67.40%.
What is Jeffrey Brennan's role in Gyre Therapeutics?
Jeffrey Brennan's role in Gyre Therapeutics is SVP, Bus. and Comm. Dev. & CBO.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.

TipRanks measures corporate insiders by the stock transactions they report to the SEC. See how TipRanks ranks experts and calculates performance.